Literature DB >> 25724691

Understanding mammalian glutathione peroxidase 7 in the light of its homologs.

Matilde Maiorino1, Valentina Bosello-Travain2, Giorgio Cozza3, Giovanni Miotto2, Antonella Roveri2, Stefano Toppo2, Mattia Zaccarin2, Fulvio Ursini2.   

Abstract

The glutathione peroxidase homologs (GPxs) efficiently reduce hydroperoxides using electrons from glutathione (GSH), thioredoxin (Trx), or protein disulfide isomerase (PDI). Trx is preferentially used by the GPxs of the majority of bacteria, invertebrates, plants, and fungi. GSH or PDI, instead, is preferentially used by vertebrate GPxs that operate by Sec or Cys catalysis, respectively. Mammalian GPx7 and GPx8 are unique homologs that contain a peroxidatic Cys (CP). Being reduced by PDI and located within the endoplasmic reticulum (ER), these enzymes have been involved in oxidative protein folding. Kinetic analysis indicates that oxidation of PDI by recombinant GPx7 occurs at a much faster rate than that of GSH. Nonetheless, activity measurement suggests that, at physiological concentrations, a competition between these two substrates takes place, with the rate of PDI oxidation by GPx7 controlled by the concentration of GSH, whereas the GSSG produced in the competing reaction contributes to the ER redox buffer. A mechanism has been proposed for GPx7 involving two Cys residues, in which an intramolecular disulfide of the CP is formed with an alleged resolving Cys (CR) located in the strongly conserved FPCNQ motif (C86 in humans), a noncanonical position in GPxs. Kinetic measurements and comparison with the other thiol peroxidases containing a functional CR suggest that a resolving function of C86 in the catalytic cycle is very unlikely. We propose that GPx7 is catalytically active as a 1-Cys-GPx, in which CP both reduces H2O2 and oxidizes PDI, and that the CP-C86 disulfide has instead the role of stabilizing the oxidized peroxidase in the absence of the reducing substrate.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Free radicals; GPx; GSH; Hydroperoxide; Kinetic; PDI; Resolving cysteine; Thioredoxin

Mesh:

Substances:

Year:  2015        PMID: 25724691     DOI: 10.1016/j.freeradbiomed.2015.02.017

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

1.  Characterization of the endoplasmic reticulum-resident peroxidases GPx7 and GPx8 shows the higher oxidative activity of GPx7 and its linkage to oxidative protein folding.

Authors:  Shingo Kanemura; Elza Firdiani Sofia; Naoya Hirai; Masaki Okumura; Hiroshi Kadokura; Kenji Inaba
Journal:  J Biol Chem       Date:  2020-07-21       Impact factor: 5.157

Review 2.  Chemistry and Enzymology of Disulfide Cross-Linking in Proteins.

Authors:  Deborah Fass; Colin Thorpe
Journal:  Chem Rev       Date:  2017-07-12       Impact factor: 60.622

Review 3.  The Incomplete Glutathione Puzzle: Just Guessing at Numbers and Figures?

Authors:  Marcel Deponte
Journal:  Antioxid Redox Signal       Date:  2017-07-19       Impact factor: 8.401

Review 4.  The Intestinal Redox System and Its Significance in Chemotherapy-Induced Intestinal Mucositis.

Authors:  Qing-Qing Yu; Heng Zhang; Yujin Guo; Baoqin Han; Pei Jiang
Journal:  Oxid Med Cell Longev       Date:  2022-05-09       Impact factor: 7.310

5.  The Cluster Transfer Function of AtNEET Supports the Ferredoxin-Thioredoxin Network of Plant Cells.

Authors:  Sara I Zandalinas; Luhua Song; Rachel Nechushtai; David G Mendoza-Cozatl; Ron Mittler
Journal:  Antioxidants (Basel)       Date:  2022-08-06

6.  Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions.

Authors:  Marine Lénon; Na Ke; Cecily Szady; Hassan Sakhtah; Guoping Ren; Bruno Manta; Bryce Causey; Mehmet Berkmen
Journal:  Appl Microbiol Biotechnol       Date:  2020-09-30       Impact factor: 4.813

Review 7.  Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer.

Authors:  Supriya Bevinakoppamath; Adel Mohammed Saleh Ahmed; Shobha Chikkavaddaraguddi Ramachandra; Prashant Vishwanath; Akila Prashant
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.